Skip to main content

Chevallard Daniel R.'s Form 4 filing

Viracta Therapeutics, Inc.VIRX · filed Aug 29, 2022

Accession no.
0001209191-22-047948
Filed
Aug 29, 2022
Trade date
Aug 25-26, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $14.7K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Chevallard Daniel R.CIK 0001706176Officer (CFO and COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 25, 2022Common StockMOption exerciseAcquired+6,889$0.00F1$086,031Direct
Aug 26, 2022Common StockSSaleDisposed−3,655$4.02F3−$14,693.182,376Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 25, 2022Common StockMOption exerciseDisposed−6,889$0.00$075,777Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average share price of an aggregate total of 3,655 shares sold in the price range of $4.01 to $4.13 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)